A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Por:
Gonzalez A, Lluch A, Aba E, Albanell J, Anton A, Alvarez I, Ayala F, Barnadas A, Calvo L, Ciruelos E, Cortes J, de la Haba J, Lopez-Vega J, Martinez E, Munoz M, Pelaez I, Redondo A, Rodriguez A, Rodriguez C, Ruiz A, Llombart A
Publicada:
1 may 2017
Resumen:
To converge on an expert opinion to define aggressive disease in patients with HER2-negative mBC using a modified Delphi methodology.
A panel of 21 breast cancer experts from the Spanish Society of Medical Oncology agreed upon a survey which comprised 47 questions that were grouped into three sections: relevance for defining aggressive disease, aggressive disease criteria and therapeutic goals. Answers were rated using a 9-point Likert scale of relevance or agreement.
Among the 88 oncologists that were invited to participate, 81 answered the first round (92%), 70 answered the second round (80%), and 67 answered the third round (76%) of the survey. There was strong agreement regarding the fact that identifying patients with aggressive disease needs to be adequately addressed to help practitioners to decide the best treatment options for patients with HER2-negative mBC. The factors that were considered to be strongly relevant to classifying patients with aggressive HER2-negative mBC were a high tumor burden, a disease-free interval of less than 12-24 months after surgery, the presence of progressive disease during adjuvant or neoadjuvant chemotherapy and having a triple-negative phenotype. The main therapeutic goals were controlling symptoms, improving quality of life and increasing the time to progression and overall survival.
High tumor burden, time to recurrence after prior therapy and having a triple-negative phenotype were the prognostic factors for which the greatest consensus was found for identifying patients with aggressive HER2-negative mBC. Identifying patients with aggressive disease leads to different therapeutic approaches.
Filiaciones:
Gonzalez A:
MD Anderson Canc Ctr, Dept Med Oncol, C Arturo Soria 270, Madrid 28033, Spain
Lluch A:
Hosp Clin Univ Valencia, Dept Hematol & Oncol, Valencia, Spain
Aba E:
Hosp Univ Virgen Victoria, Dept Med Oncol, Malaga, Spain
Albanell J:
Hosp Parc Salut Mar, Dept Med Oncol, Barcelona, Spain
Anton A:
Hosp Miguel Servet, Dept Med Oncol, Zaragoza, Spain
Alvarez I:
Hosp Univ Donostia, Dept Med Oncol, San Sebastian, Spain
Ayala F:
Hosp Univ Morales Meseguer, Dept Med Oncol, Murcia, Spain
Barnadas A:
Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
Calvo L:
Complejo Hosp Univ La Coruna, Dept Med Oncol, La Coruna, Spain
Ciruelos E:
Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
Cortes J:
Hosp Univ Ramon & Cajal, Dept Med Oncol, Madrid, Spain
de la Haba J:
Hosp Univ Reina Sofia, Dept Med Oncol, Cordoba, Spain
Lopez-Vega J:
Hosp Univ Marques de Valdecilla, Dept Med Oncol, Santander, Spain
Martinez E:
Fdn Hosp Prov Castellon, Dept Med Oncol, Castellon de La Plana, Spain
Munoz M:
Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
Pelaez I:
Hosp Cabuenes, Dept Med Oncol, Gijon, Spain
Redondo A:
Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain
Rodriguez A:
Hosp Gen Univ Elche, Dept Med Oncol, Elche, Spain
Rodriguez C:
Hosp Univ Salamanca IBSAL, Dept Med Oncol, Salamanca, Spain
Ruiz A:
Inst Valenciano Oncol, Valencia, Spain
Llombart A:
Hosp Arnau Vilanova, Dept Med Oncol, Lleida, Spain
|